Aditxt 2025 Q3 Earnings Net Loss Widens 246.8% to $24.21 Million

Aditxt (ADTX) reported a sharp decline in revenue and a widened net loss for Q3 2025, alongside a strategic pivot to bitXbio. The company announced a name change to bitXbio, Inc., and plans to launch a digital asset treasury, while its subsidiaries Pearsanta and Evofem aim for IPOs and relisting.

Revenue

Aditxt's total revenue plummeted to $748 million in Q3 2025, a sharp decline from $6,854 million in the same period last year. The entire revenue came from sales, with no additional segments contributing to the top line.

Earnings/Net Income

The company narrowed its per-share loss to $548.78 from $3.14 million in 2024 Q3, but the net loss widened to $24.21 million in 2025 Q3, representing a 246.8% increase from $6.98 million in 2024 Q3. Despite a 100% improvement in per-share losses, the company's net loss widened significantly, underscoring ongoing financial challenges.

Post-Earnings Price Action Review

The stock price of Aditxt dropped 4.90% during the latest trading day, plummeted 30.96% during the most recent full trading week, and surged 1151.15% month-to-date.

Additional News

1. Name Change & Strategic Shift: Aditxt filed for a name change to bitXbio, Inc., aligning with its blockchain-integrated health innovation strategy.

2. Employee Stock Purchase Plan (ESPP): A proposed ESPP aims to align employees with shareholders, enhancing ownership culture.

3. Subsidiary Plans: Pearsanta, Aditxt’s precision diagnostics unit, plans an IPO in 2026, while Evofem seeks to regain a national listing and secure growth capital.

Additional News

The company’s digital asset treasury (DAT) strategy includes a crypto reserve, utility token, and tokenized ventures, though no digital assets are currently held. Pearsanta’s Mitomic® and Adductomics platforms are advancing clinical validation, while Evofem markets PHEXXI® and SOLOSEC®. Aditxt’s pivot to bitXbio reflects a broader vision to merge blockchain, public markets, and health innovation.

Image rule: